地诺孕素与子宫内膜异位症术后复发风险:系统综述与荟萃分析
该系统综述与荟萃分析检索多个数据库至2019年3月,纳入10项研究共1184例地诺孕素治疗患者和846例期待管理对照。地诺孕素组复发率为每100名女性2例(95%CI 1.43-3.11),期待管理组为每100名女性29例(95%CI 25.66-31.74),术后地诺孕素显著降低复发风险(log odds -1.96,95%CI -2.53至-1.38,P<.001)。
要点
- 子宫内膜异位症保守手术后使用地诺孕素可显著降低复发风险。
- 地诺孕素组平均随访29个月复发率2/100女性,期待管理组平均随访36个月为29/100女性。
- 复发可能性在地诺孕素组显著降低(log odds -1.96,95%CI -2.53至-1.38,P<.001)。
核心结论
- 子宫内膜异位症保守手术后接受地诺孕素治疗的患者,术后疾病复发风险显著低于期待管理患者。
研究设计与样本
- 系统综述与荟萃分析,检索Ovid MEDLINE、Ovid EMBASE、PubMed、Cochrane Central Register of Controlled Trials、Web of Science、LILACS、clinicaltrials.gov及ISRCTN注册库,自建库至2019年3月。
- 检索获得328项研究,最终纳入10项符合条件的研究,共1184例地诺孕素治疗患者和846例期待管理对照。
- 纳入研究中9项仅观察子宫内膜异位囊肿复发,1项以症状再现作为疾病复发证据。
主要发现
- 地诺孕素治疗患者子宫内膜异位症复发率为每100名女性2例(95%CI 1.43-3.11),平均随访29个月。
- 期待管理对照组复发率为每100名女性29例(95%CI 25.66-31.74),平均随访36个月。
- 术后地诺孕素使复发可能性显著降低(log odds -1.96,95%CI -2.53至-1.38,P<.001)。
临床怎么用
- 对于接受保守手术的子宫内膜异位症患者,术后可考虑使用地诺孕素以降低复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To determine whether dienogest therapy after endometriosis surgery reduces the risk of endometriosis recurrence compared with expectant management. DATA SOURCES: Ovid MEDLINE, Ovid EMBASE, PubMed, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, clinicaltrials.gov, and International Standard Randomized Controlled Trial Number Registry were searched from inception to March 2019 for observational and randomized controlled trials. METHODS OF STUDY SELECTION: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Medical Subject Heading terms and keywords such as "dienogest," "endometriosis," and "recurrence" were used to identify relevant studies. TABULATION, INTEGRATION, AND RESULTS: The search yielded 328 studies, 10 of which were eligible for inclusion, representing 1184 patients treated with dienogest and 846 expectantly managed controls. Among these studies, 9 looked exclusively at endometrioma recurrence, whereas 1 used reappearance of symptoms as evidence of disease recurrence. Data on both incidence of and time to recurrence of endometriosis were extracted. The incidence rate of endometriosis recurrence in patients treated with dienogest was 2 per 100 women over a mean follow-up of 29 months (95% confidence interval [CI], 1.43-3.11) versus 29 per 100 women managed expectantly over a mean follow-up of 36 months (95% CI, 25.66-31.74). The likelihood of recurrence was significantly reduced with postoperative dienogest (log odds -1.96, CI, -2.53 to -1.38, p <.001). CONCLUSION: Patients receiving dienogest after conservative surgery for endometriosis had significantly lower risk of postoperative disease recurrence than those who were expectantly managed.
引用
- Zakhari A, Edwards D, Ryu M, et al. Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2020. PMID: 32428571. doi:10.1016/j.jmig.2020.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。